Published in Invest Ophthalmol Vis Sci on July 29, 2011
miRNAs in the vitreous humor of patients affected by idiopathic epiretinal membrane and macular hole. PLoS One (2017) 1.39
Inflammatory mechanisms of idiopathic epiretinal membrane formation. Mediators Inflamm (2013) 0.99
Gene expression of IGF1, IGF1R, and IGFBP3 in epiretinal membranes of patients with proliferative diabetic retinopathy: preliminary study. Mediators Inflamm (2013) 0.83
Neurotrophins and neurotrophin receptors in proliferative diabetic retinopathy. PLoS One (2013) 0.83
Spontaneous release of epiretinal membrane in a young weight-lifting athlete by presumed central rupture and centrifugal pull. Clin Ophthalmol (2014) 0.80
Clinical and histological features of epiretinal membrane after diabetic vitrectomy. Graefes Arch Clin Exp Ophthalmol (2013) 0.79
Epiretinal membranes in patients with uveitis: morphological and functional analysis with spectral domain optical coherence tomography. Biomed Res Int (2013) 0.78
Gene Expression Analysis of the Irrigation Solution Samples Collected during Vitrectomy for Idiopathic Epiretinal Membrane. PLoS One (2016) 0.75
Pathologic Roles of Receptor-Associated Prorenin System in Idiopathic Epiretinal Membrane. Sci Rep (2017) 0.75
Foveal contour changes following surgery for idiopathic epiretinal membrane. Invest Ophthalmol Vis Sci (2014) 0.75
Soluble form of LR11 is highly increased in the vitreous fluids of patients with idiopathic epiretinal membrane. Graefes Arch Clin Exp Ophthalmol (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol Cell (2007) 7.09
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A (2005) 2.13
ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem (2005) 2.11
Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med (2010) 2.10
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci U S A (2013) 1.94
Beta-amyloid monomers are neuroprotective. J Neurosci (2009) 1.87
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci (2004) 1.66
Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci (2005) 1.57
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle (2009) 1.54
Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) (2009) 1.50
In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle (2011) 1.46
Vitamin D3: a helpful immuno-modulator. Immunology (2011) 1.46
Functional characterization of WNT7A signaling in PC12 cells: interaction with A FZD5 x LRP6 receptor complex and modulation by Dickkopf proteins. J Biol Chem (2003) 1.44
Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci (2006) 1.42
Akt as a therapeutic target in cancer. Expert Opin Ther Targets (2008) 1.41
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol (2011) 1.40
Editorial. Curr Neuropharmacol (2006) 1.40
TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res (2008) 1.40
The conditioned eyeblink reflex: a potential tool for the detection of cerebellar dysfunction in multiple sclerosis. Mult Scler (2011) 1.39
Metabotropic glutamate 1 receptor: current concepts and perspectives. Pharmacol Rev (2008) 1.38
The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J Neurosci (2007) 1.38
Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology (2005) 1.36
Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death. J Neurosci (2005) 1.32
Bcl-2 and Bax exert opposing effects on Ca2+ signaling, which do not depend on their putative pore-forming region. J Biol Chem (2004) 1.31
Inorganic polyphosphate and energy metabolism in mammalian cells. J Biol Chem (2010) 1.30
Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am J Ophthalmol (2006) 1.29
Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res (2008) 1.26
Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer (2002) 1.22
Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology (2012) 1.21
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle (2010) 1.18
The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol Sci (2003) 1.17
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle (2011) 1.17
Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur J Pharmacol (2009) 1.16
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget (2011) 1.16
Emerging MEK inhibitors. Expert Opin Emerg Drugs (2010) 1.16
Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol (2006) 1.14
Induction of the Wnt inhibitor, Dickkopf-1, is associated with neurodegeneration related to temporal lobe epilepsy. Epilepsia (2007) 1.14
Induction of the Wnt antagonist, Dickkopf-1, contributes to the development of neuronal death in models of brain focal ischemia. J Cereb Blood Flow Metab (2008) 1.13
Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes. J Immunol (2003) 1.09
Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol (2005) 1.09
Mitochondrial Atpif1 regulates haem synthesis in developing erythroblasts. Nature (2012) 1.09
Prenatal restraint stress generates two distinct behavioral and neurochemical profiles in male and female rats. PLoS One (2008) 1.08
Resistance to TRAIL and how to surmount it. Immunol Res (2012) 1.08
Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease. Ophthalmology (2009) 1.06
Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J Neurosci (2006) 1.06
Advances in targeting signal transduction pathways. Oncotarget (2012) 1.06
Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J Cell Physiol (2008) 1.05
Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J Neurochem (2004) 1.05
TGF-beta 1 protects against Abeta-neurotoxicity via the phosphatidylinositol-3-kinase pathway. Neurobiol Dis (2008) 1.04
Mitochondrial ND5 gene variation associated with encephalomyopathy and mitochondrial ATP consumption. J Biol Chem (2007) 1.04
BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology (2012) 1.04
REN: a novel, developmentally regulated gene that promotes neural cell differentiation. J Cell Biol (2002) 1.03
Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J Neurochem (2003) 1.03
Molecular Regulation of the Mitochondrial F(1)F(o)-ATPsynthase: Physiological and Pathological Significance of the Inhibitory Factor 1 (IF(1)). Int J Cell Biol (2012) 1.03
Metabotropic glutamate receptors in glial cells. Neurochem Res (2008) 1.02
Metabotropic glutamate receptors in stem/progenitor cells. Neuropharmacology (2007) 1.01
Role of G protein-coupled receptor kinase 4 and beta-arrestin 1 in agonist-stimulated metabotropic glutamate receptor 1 internalization and activation of mitogen-activated protein kinases. J Biol Chem (2003) 1.01
Microperimetric biofeedback in AMD patients. Appl Psychophysiol Biofeedback (2007) 1.00
Experience-induced Arc/Arg3.1 primes CA1 pyramidal neurons for metabotropic glutamate receptor-dependent long-term synaptic depression. Neuron (2013) 1.00
Potential use of rapamycin in HIV infection. Br J Clin Pharmacol (2010) 1.00
Metabotropic glutamate receptors and the control of chronic pain. Curr Opin Pharmacol (2011) 1.00
Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol Dis (2006) 1.00
DNA polymerase-beta is expressed early in neurons of Alzheimer's disease brain and is loaded into DNA replication forks in neurons challenged with beta-amyloid. J Neurosci (2006) 0.99
Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci (2004) 0.99
Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice. Neuropsychopharmacology (2011) 0.99
Group I metabotropic glutamate receptors: a role in neurodevelopmental disorders? Mol Neurobiol (2007) 0.99
Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. Trends Pharmacol Sci (2010) 0.99
Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells. J Neurochem (2006) 0.98
Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J Neurosci (2002) 0.98
Interaction between ephrins/Eph receptors and excitatory amino acid receptors: possible relevance in the regulation of synaptic plasticity and in the pathophysiology of neuronal degeneration. J Neurochem (2006) 0.98
Genome-wide RNAi screen identifies ATPase inhibitory factor 1 (ATPIF1) as essential for PARK2 recruitment and mitophagy. Autophagy (2013) 0.97
Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia (2010) 0.97
Activation of group II metabotropic glutamate receptors promotes DNA demethylation in the mouse brain. Mol Pharmacol (2011) 0.97
Insulin secretion is controlled by mGlu5 metabotropic glutamate receptors. Mol Pharmacol (2006) 0.96
Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1. Mol Brain (2013) 0.96
MGluR5 mediates the interaction between late-LTP, network activity, and learning. PLoS One (2008) 0.96
Targeting the cancer initiating cell: the ultimate target for cancer therapy. Curr Pharm Des (2012) 0.96
TGF-β1 pathway as a new target for neuroprotection in Alzheimer's disease. CNS Neurosci Ther (2009) 0.96
A novel rat gene encoding a Humanin-like peptide endowed with broad neuroprotective activity. FASEB J (2002) 0.95
Dysfunction of TGF-β1 signaling in Alzheimer's disease: perspectives for neuroprotection. Cell Tissue Res (2011) 0.95
Optical coherence tomography for classification and clinical evaluation of macular edema in patients with uveitis. Ocul Immunol Inflamm (2008) 0.95
Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia. Eur J Neurosci (2006) 0.94